Istvan Laszlovszky
Affiliations: | Pharmaceutical Research Laboratories, Hungary, Veszprém, Hungary |
Google:
"Istvan Laszlovszky"Mean distance: 14.17 (cluster 17) | S | N | B | C | P |
Cross-listing: Chemistry Tree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kiss B, Krámos B, Laszlovszky I. (2022) Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D Receptors in the Brain . Frontiers in Psychiatry. 13: 785592 |
| Laszlovszky I, Barabássy Á, Németh G. (2021) Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy |
| Barabássy Á, Sebe B, Acsai K, et al. (2021) Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatric Disease and Treatment. 17: 957-970 |
| Laszlovszky I, Kiss B, Barabassy A, et al. (2019) [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology. 21: 103-118 |
| Fleischhacker W, Galderisi S, Laszlovszky I, et al. (2019) The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry : the Journal of the Association of European Psychiatrists. 58: 1-9 |
| Laszlovszky I, Barabassy A, Kiss B, et al. (2019) Cariprazine, a selective dopamine D3 receptor partial agonist with unique features to treat schizophrenia negative and cognitive symptoms European Neuropsychopharmacology. 29: S398-S399 |
| Marder S, Fleischhacker WW, Earley W, et al. (2018) Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |
| Durgam S, Earley W, Lu K, et al. (2017) Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. International Journal of Clinical Practice |
| Nasrallah HA, Earley W, Cutler AJ, et al. (2017) The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. Bmc Psychiatry. 17: 305 |
| Earley W, Durgam S, Lu K, et al. (2017) Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. International Clinical Psychopharmacology |